Here are the 10-K annual reports from Vitanova Life Sciences (VNOV) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VNOV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VNOV filings page.
VitaNova Life Sciences Corporation, a Nevada-based consumer health company, sells dietary supplements under its GeneCode and AMZ brands and, since 2026, healthy food products through VitaNova Global Foods, plus a small consulting business. Revenue for the year ended April 30, 2026 was $3,025,538, including $1,947,620 from supplements, $1,062,918 from food products and $15,000 from consulting.
Gross profit was $910,589, with margin compressing to 30% from 59% as lower-margin food products and promotional pricing offset growth. General and administrative expenses increased to $733,795, largely from higher legal, professional and stock-compensation costs, resulting in a net loss of $37,304 versus prior-year net income of $850,746. The company generated $814,407 of operating cash flow, ended the year with $1,597,217 in cash and total current liabilities of $395,781, and had 8,337,454 common shares outstanding. Revenue is concentrated in a small number of customers and suppliers, and operations rely on third-party manufacturers operating under U.S. dietary-supplement and food-safety regulations.